论文部分内容阅读
膀胱癌是欧洲第5大常见癌症,每年诊断的新病例约151000例,并且每年有超过52000例死亡病例。但在过去几十年中,膀胱癌治疗方法的进展很少。其中,尿路上皮癌是最常见的类型,约占90%。日前,欧盟批准百时美施贵宝Opdivo在欧洲获得了第8个适应症的批准。此药除了使用于转移性尿路上皮癌(MUC)患者群体之外,欧盟委员会正准备批准该药物用于治疗局部肿瘤晚期不可切除或既往使用铂化疗失败的MUC成人患者,这个批准将使Opdivo成为该地区唯一可用于这种膀胱癌的免疫肿瘤药物。德国
Bladder cancer is the fifth most common cancer in Europe with 151,000 new cases diagnosed annually and more than 52,000 deaths annually. However, little progress has been made in the treatment of bladder cancer over the past few decades. Among them, urothelial carcinoma is the most common type, accounting for about 90%. Recently, the EU approved Bristol-Myers Squibb Opdivo obtained the approval of the 8th indication in Europe. In addition to being used in a population of patients with metastatic urothelial carcinoma (MUC), the European Commission is preparing to approve the drug for the treatment of adult MUC patients with locally advanced unresectable or previously unsuccessful platinum-based chemotherapy in a local tumor that will allow Opdivo Become the only immune tumor drug available for this bladder cancer in the area. Germany